•A randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
(REDUCE-Multicentre Study)
•An Epidemiologic Study of Patients with Cancer and Skeletal-related Complications
(Department of Epidemiology, Medical School, Athens University)
•A Phase IIB Trial to Determine the Efficacy and Safety of ONY-P Vaccines in the Management of Prostate Cancer without Detectable Metastases Following Initial Escape from Prostate Cancer
(Department of Urological Oncology, University of Surrey, UK)